TherapeuticsMD Inc (NASDAQ:TXMD) struck success with the FDA for its menopause drug TX-001HR, an oral combination of estradiol and progesterone. The company’s NDA for the drug has won a green light for review come October 28th as a treatment of moderate-to-severe vasomotor symptoms related to menopause. Should TXMD get an ultimate nod, the launch is anticipated for the first quarter of next year.
Oppenheimer analyst Jay Olson is highlighting an upbeat bullish stance for a biotech stock he sees on the brink of a “massive transformation.”
In reaction to the good news, the analyst reiterates an Outperform rating on TXMD stock with a $10 price target, which implies a close to 69% upside from current levels. (To watch Olson’s track record, click here)
“We are increasingly optimistic about the setup for TXMD shares with 2 potential FDA approvals this year […] TX-001HR could become the first FDA-approved, third-party reimbursed bio-identical combination treatment option for menopausal symptoms including night sweats, hot flashes, and sleep disturbances. TXMD has a May 29 PDUFA for TX-004HR, the company’s estradiol vaginal softgel capsule for dyspareunia, a symptom of vulvar and vaginal atrophy (VVA) due to menopause. We believe TXMD is on the verge of massive transformation,” cheers Olson.
True, the company got an FDA rejection back in May of last year for TX-004HR as a vaginal pain medicine. However, the biotech maker is on its way to an exciting comeback, and bulls across the Street are taking notice.
“After getting sidetracked by the FDA in 2017, TXMD is making steady progress with 2 PDUFA’s in 2018. We expect TXMD shares to start getting more credit for the commercial potential of 2 innovative new women’s health products that may receive FDA approval this year,” Olson contends.
Looking ahead, the analyst pinpoints TX-001HR as the bigger of the company’s two best prospects, calculating roughly $450 million in risk-adjusted sales by 2025.
TipRanks pinpoints predominantly strong bullish word circulating TXMD shares. All 5 analysts polled in the last 3 months rate a Buy on this healthcare stock. With a massive return potential of 188%, the stock’s consensus target price hits a high $15.50.